Description: Nuo Therapeutics, Inc., a regenerative therapies company, develops, commercializes, and markets cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing primarily in the United States. Its technology separates autologous blood to produce a platelet based therapy for the chronic wound care market. The company was formerly known as Cytomedix, Inc. and changed its name to Nuo Therapeutics, Inc. in November 2014. Nuo Therapeutics, Inc. was founded in 1998 and is based in Gaithersburg, Maryland.
Home Page: www.nuot.com
8285 El Rio
Houston,
TX
77054
United States
Phone:
346 396 4770
Officers
| Name | Title |
|---|---|
| Mr. David E. Jorden CPA | CEO, CFO, Sec. & Exec. Director |
| Dr. Peter Anton Clausen Ph.D. | COO & Chief Scientific Officer |
| Ms. Jennifer Grayson | Head of Comprehensive Clinical Trial Data Audit |
| Mr. Shaun M. Martin | Chief Restructuring Officer |
| Dr. David F. Counts | Consultant |
| Mr. Joseph Del Guercio | Informal Board Advisor |
Exchange: OTCQB
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 20.4308 |
| Price-to-Sales TTM: | 1682.8878 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 4 |